# US 2021/0228498 A1 · Methods of permeabilizing the blood brain barrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228498 A1
- Document ID: US20210228498A1
- Status: Published application
- Kind: A1
- Application number: 16/967,549
- Filed: 2019-02-07
- Published: 2021-07-29
- Earliest claimed: 2018-02-08
- Assignees: NeOnc Technologies, Inc.
- Applicants: NeOnc Technologies, Inc.
- Inventors: Thomas CHEN
- Web page: https://patentgrep.com/patent/US20210228498A1

## CPC

- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/415: 1,2-Diazoles
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07C 13/23: with a cyclohexadiene ring
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/42: against immunoglobulins
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/544: {to the airways}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2319/03: containing a transmembrane segment
- C12N 5/16: Animal cells
- C12P 5/007: {containing one or more isoprene units, i.e. terpenes (carotenes C12P23/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

## Claims

### Claim 1

A method of administering a therapeutic agent to a central nervous system of a mammal, the method comprising administering a monoterpene before or concurrently with the therapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the central nervous system is the brain.

### Claim 3 (depends on 1)

The method of claim 1, wherein the monoterpene is perillyl alcohol.

### Claim 4 (depends on 3)

The method of claim 3, wherein perillyl alcohol is administered intraarterially.

### Claim 5 (depends on 3)

The method of claim 3, wherein perillyl alcohol is administered at a dose ranging from about 0.050 mg/kg to about 500 mg/kg of body weight.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein the monoterpene is administered from about 0.2 minutes to about 60 minutes before the therapeutic agent is administered.

### Claim 8 (depends on 7)

The method of claim 7, wherein the monoterpene is administered from about 1 minute to about 15 minutes before the therapeutic agent is administered.

### Claim 9 (depends on 1)

The method of claim 1, wherein the monoterpene and the therapeutic agent are administered separately.

### Claim 10 (depends on 1)

The method of claim 1, wherein the monoterpene and the therapeutic agent are administered concurrently.

### Claim 11 (depends on 10)

The method of claim 10, wherein the monoterpene and the therapeutic agent are administered together in a pharmaceutical composition.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutic agent is a chemotherapeutic agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the chemotherapeutic agent is selected from the group consisting of a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, a receptor antagonist, a therapeutic antibody, and combinations thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein the chemotherapeutic agent is dimethyl-celecoxib (DMC), irinotecan (CPT-11), temozolomide or rolipram.

### Claim 15 (depends on 1)

The method of claim 1, wherein the therapeutic agent is an antibody or antibody fragment.

### Claim 16 (depends on 1)

The method of claim 1, wherein the therapeutic agent is an immune cell expressing a chimeric antigen receptor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the immune cell is a T cell.

### Claim 18 (depends on 16)

The method of claim 16, wherein the therapeutic agent is a CAR-T cell.

### Claim 19 (depends on 1)

The method of claim 1, wherein the monoterpene is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

### Claim 20 (depends on 1)

The method of claim 1, wherein the mammal has cancer.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer is a tumor of the nervous system.

### Claim 22 (depends on 21)

The method of claim 21, wherein the tumor is a glioblastoma.

### Claim 23 (depends on 1)

The method of claim 1, further comprising treating the mammal with radiation.
